Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss

被引:24
作者
Mar, Nataliya [1 ]
Kosowicz, Rebecca [2 ]
Hook, Karen [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, Dept Hematol Oncol, Farmington, CT 06030 USA
[2] Univ Connecticut, Sch Med, Farmington, CT 06030 USA
关键词
Catastrophic antiphospholipid syndrome; Thrombosis; Intravenous immunoglobulin; Hydroxychloroquine; Pregnancy; Thrombocytopenia; MOLECULAR-WEIGHT HEPARIN; DOSE HEPARIN; ANTIBODIES; THROMBOCYTOPENIA; MULTICENTER; PREDNISONE; TRIAL;
D O I
10.1007/s11239-014-1061-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report a case of a 36-year old patient with prior history of thrombosis in a setting of antiphospholipid antibody syndrome (APS) as well as pregnancy-associated catastrophic antiphospholipid syndrome (CAPS), resulting in multi-organ infarction and pregnancy loss. The episode of CAPS occurred while she was receiving antepartum low-dose aspirin and therapeutic-dose enoxaparin. This patient presented again at 6 weeks gestation and ultra-sounds were consistent with fetal growth restriction, concerning for placental insufficiency and thrombosis. This time, hydroxychloroquine and monthly intravenous immunoglobulin (IVIG) infusions were added to her prophylaxis regimen, resulting in a successful delivery. Platelet count and antiphospholipid antibody titers were routinely monitored throughout pregnancy as markers of disease activity for APS. Current thromboprophylaxis guidelines do not address therapeutic options to prevent further pregnancy morbidity in women who develop recurrent episodes of thrombosis or CAPS despite receiving adequate anti-thrombotic treatment. Use of hydroxychloroquine and IVIG has been associated with good outcomes in this subset of patients.
引用
收藏
页码:196 / 200
页数:5
相关论文
共 32 条
[1]   Risk factors for venous thromboembolism [J].
Anderson, FA ;
Spencer, FA .
CIRCULATION, 2003, 107 :I9-I16
[2]   Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].
Asherson, RA ;
Cervera, R ;
de Groot, PG ;
Erkan, D ;
Boffa, MC ;
Piette, JC ;
Khamashta, MA ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :530-534
[3]   VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Bates, Shannon M. ;
Greer, Ian A. ;
Middeldorp, Saskia ;
Veenstra, David L. ;
Prabulos, Anne-Marie ;
Vandvik, Per Olav .
CHEST, 2012, 141 (02) :E691S-E736S
[4]   HYPERCOAGULABILITY AND THROMBOSIS [J].
BICK, RL .
MEDICAL CLINICS OF NORTH AMERICA, 1994, 78 (03) :635-665
[5]   A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy [J].
Branch, DW ;
Peaceman, AM ;
Druzin, M ;
Silver, RK ;
El-Sayed, Y ;
Silver, RM ;
Esplin, MS ;
Spinnato, J ;
Harger, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 182 (01) :122-127
[6]   Catastrophic antiphospholipid syndrome [J].
Cervera, Ricard ;
Asherson, Ronald A. .
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2006, 35 (1-2) :181-186
[7]   REPEATED FETAL LOSSES ASSOCIATED WITH ANTIPHOSPHOLIPID ANTIBODIES - A COLLABORATIVE RANDOMIZED TRIAL COMPARING PREDNISONE WITH LOW-DOSE HEPARIN TREATMENT [J].
COWCHOCK, FS ;
REECE, EA ;
BALABAN, D ;
BRANCH, DW ;
PLOUFFE, L .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (05) :1318-1323
[8]  
Di Prima Fosca A F, 2011, J Prenat Med, V5, P41
[9]   The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome [J].
Diz-Kucukkaya, Reyhan ;
Hancer, Veysel Sabri ;
Artim-Esen, Bahar ;
Pekcelen, Yuksel ;
Inanc, Murat .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2010, 29 (03) :303-309
[10]  
DUHEM C, 1994, CLIN EXP IMMUNOL, V97, P79